NY-ESTÉE-LAUDER
5.4.2024 15:26:35 CEST | Business Wire | Press release
TOM FORD announced today that Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. King will step into this role effective April 1, 2024 and continue reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies. King will also join The Estée Lauder Companies (NYSE:EL) Extended Executive Leadership Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240405576513/en/
Dexter King has been appointed Senior Vice President, Global General Manager, TOM FORD BEAUTY. (Photo: Business Wire)
King has been with TOM FORD BEAUTY for nine years, working in a number of key leadership roles including most recently as Senior Vice President (SVP), Global Marketing and Strategy, and prior to then as SVP, General Manager, International and Global Strategy. In close partnership with Jesel, under King’s leadership of strategy and International, the brand elevated key TOM FORD fragrances to the luxury tier, accelerated its channel strategy and achieved exceptional growth and share gains across key markets.
“Dexter’s multi-faceted leadership experience at TOM FORD BEAUTY has been instrumental in helping the brand achieve exceptional global growth,” said Jesel. “His deep understanding of luxury, the importance of aspirational local relevance, and his command of the strategic growth opportunities in the luxury sector make him well-suited to lead the continued global momentum of TOM FORD BEAUTY.”
In his new role, King will lead the TOM FORD BEAUTY team in all aspects of category, channel and geography strategic growth plans. He will focus on driving the brand’s luxury beauty positioning through world-class innovation across makeup, fragrance and skincare and continue to elevate the brand’s signature aspirational storytelling of modern luxury glamour and amplifying individual beauty.
Prior to TOM FORD BEAUTY, King worked in strategy and marketing roles, holding positions of increasing responsibility across companies including McKinsey & Company, Diageo, and Moët Hennessy. King holds a Master of Business Administration from The Fuqua School of Business at Duke University and a Bachelor of Arts in Economics from the University of Virginia.
About TOM FORD
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. IN 2023, THE ESTÉE LAUDER COMPANIES BECAME THE SOLE OWNER OF THE TOM FORD BRAND AND ALL ITS INTELLECTUAL PROPERTY. IN APRIL 2023 PETER HAWKINGS WAS APPOINTED THE CREATIVE DIRECTOR OF TOM FORD.
About TOM FORD BEAUTY
TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY PRODUCTS ACROSS WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUTY. FOUNDED IN 2005 BY TOM FORD, TODAY THE BRAND HAS A PRESENCE IN MORE THAN 100 MARKETS GLOBALLY, AND IS WIDELY RECOGNIZED AS THE ARCHITECT OF LUXURY GLAMOUR. TOM FORD BEAUTY IS DESIGNED TO AMPLIFY INDIVIDUAL BEAUTY WITH A COLLECTION OF SUMPTUOUS COSMETICS, EXTRAORDINARY FRAGRANCES AND ADVANCED SKINCARE.
ELC-B
NYSE: EL
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240405576513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom